Reposted by Shweta Shah
BREAKING: The FDA has approved Travere Therapeutics Filspari (sparsentan) to treat adults and children ages 8+ with focal segmental glomerulosclerosis (FSGS), reducing proteinuria. As the first and only FDA-approved treatment for #FSGS, it offers new hope for patients: bit.ly/481S6iA